SBIR/STTR Research Award

Immunoassay for diagnosis of invasive fungal disease

Award identifier 5e39ba1c79ea1cbc0d335b77ca9ca88f4ab35045a0166c985571878aceeb421cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$600,000

Program and phase

STTR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Immuno-mycologics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
CN4DMLCJGCK9
Solicitation number
PA12-089
Topic code
NIAID

Research abstract

DESCRIPTION (provided by applicant): Early diagnosis of infectious disease is critical to patient outcome. An important early question is - is it a fungus, a bacterium or a virus? A rapid answer to this question would allow preemptive treatment that cansave lives. The goal of this project is a rapid and inexpensive immunoassay that will use serum as a sample to broadly identify the presence of invasive fungal disease (IFD). This is an unmet need for diagnosis of fungal infection, particularly for testsnear the point of patient care. The target population willbe individuals for whom advanced medical intervention and use of potent immunosuppressive drugs has led to a proliferation of opportunistic and endemic fungal infection. The overall hypothesis is that selected polysaccharide and protein antigens are produced by pathogenic fungi that are shared across the genera that produce invasive disease. Moreover, a subset of these antigens is shed into blood in concentrations that would allow for detection. Theapproach will be immunoassay for the presence of two distinct antigens that i) are shared across fungal species that cause IFD and ii) are shed into blood during infection. Simultaneous detection of two distinct antigens will markedly enhance the predictive value. The product will be assays with the lateral flow immunoassay (LFA) and/or enzyme-linked immunoassay (ELISA) platforms. Criteria for success in this Phase I STTR would be production of mAbs reactive with two distinct fungal antigens, one a polysaccharide and the other a protein, that are shared by the major causes of IFD. Targeting of two independent antigens will produce an assay with a high predictive value. If this Phase I project is successful, a Phase II application would construct immunoassaysin LFA or ELISA format and perform pre- clinical validation for broad diagnosis of invasive fungal disease. If successful, this translational research project could reduce mortality due to invasive fungal disease through earlier diagnosis and treatment.PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Invasive fungal disease (IFD) is one of the most devastating complications of advanced medical care and use of powerful immunosuppressive drugs. IFD is difficult to diagnose and difficult to treat.This is a translational research study whose goal is n immunoassay for early, rapid, inexpensive and non-invasive diagnosis of IFD. If successful, the project could dramatically reduce morbidity and mortality from IFD through early diagnosis and treatment.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2011–2020). Reported award amounts total $5,280,795. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.